Company: CRNX
Filing Date: 2025-02-27
Form Type: 10-K
Source: 0000950170-25-029050
Chunk: 47

Company: Crinetics Pharmaceuticals, Inc.
Filing Date: 2025-02-27
Form: 10-K
Item: Item 14
Chunk 47
---
Information required by this item will be contained in our Definitive Proxy Statement under the heading “Independent Registered Public Accountants’ Fees,” and is incorporated herein by reference.

86

PART IV 

Item 15. Exhibits, Financial Statement Schedules.

(a)Documents filed as a part of this report: 

(1)Financial Statements.

The financial statements of Crinetics Pharmaceuticals, Inc., together with the reports thereon of BDO USA, P.C., an independent registered public accounting firm, are included in this Annual Report on Form 10-K. 

(2)Financial Statement Schedules.

All schedules are omitted because they are not applicable, or the required information is shown in the financial statements or notes thereto. 

(3)Exhibits.

A list of exhibits to this Annual Report on Form 10-K is set forth on the Exhibit Index immediately preceding the signature page and is incorporated herein by reference. 

Item 16. Form 10-K Summary

None.

87

CRINETICS PHARMACEUTICALS, INC.

INDEX TO FINANCIAL STATEMENTS

    Page

    Report of Independent Registered Public Accounting Firm (BDO USA, P.C.; San Diego, California; PCAOB ID#243)
    F-2

    Consolidated Balance Sheets
    F-4

    Consolidated Statements of Operations and Comprehensive Loss
    F-5

    Consolidated Statements of Stockholders’ Equity
    F-6

    Consolidated Statements of Cash Flows
    F-7

    Notes to Consolidated Financial Statements
    F-9

F-1

Report of Independent Registered Public Accounting Firm

Stockholders and Board of Directors 

Crinetics Pharmaceuticals, Inc. 

San Diego, California

Opinion on the Consolidated Financial Statements 

We have audited the accompanying consolidated balance sheets of Crinetics Pharmaceuticals, Inc. (the “Company”) as of December 31, 2024 and 2023, the related consolidated statements of operations and comprehensive loss, stockholders’ equity, and cash flows for each of the three years in the period ended December 31, 2024, and the related notes (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2024 and 2023, and the results of its operations and its cash flows for each of the three years in the period ended December